NAD from Tryptophan: How Dietary Precursors Build NAD and the Pellagra Connection

Supplement marketers selling NMN and NR rarely mention the third major NAD source: dietary tryptophan, an essential amino acid that the body can convert into NAD⁺ through the de novo synthesis pathway. The story of how this pathway interacts with niacin status was the breakthrough that ended pellagra as a U.S. public-health crisis in the 1930s, and its modern implications for longevity-supplement choices remain under-appreciated.

The de novo pathway

Approximately 1-3 percent of dietary tryptophan is converted to NAD⁺ via the kynurenine pathway: tryptophan → kynurenine → 3-hydroxykynurenine → 3-hydroxyanthranilic acid → quinolinic acid → nicotinic acid mononucleotide → NAD⁺. The first and rate-limiting step is catalyzed by tryptophan 2,3-dioxygenase (TDO, hepatic) and indoleamine 2,3-dioxygenase (IDO, ubiquitous and induced by interferon-gamma). Roughly 60 mg of tryptophan provides the NAD⁺-equivalent of 1 mg of niacin, the basis for the niacin equivalents (NE) on nutrition labels [1].

Pellagra and the corn-tryptophan link

Pellagra — the four Ds of dermatitis, diarrhea, dementia, and death — was epidemic in the southern United States in the early 20th century, killing tens of thousands annually. Joseph Goldberger's epidemiologic work between 1914 and 1929 demonstrated it was a dietary deficiency disease, not infectious. The biochemical resolution came in 1937 when Conrad Elvehjem identified nicotinic acid (niacin) as the missing factor. The reason corn-heavy diets caused pellagra is that corn is low in tryptophan and the niacin in corn is bound in indigestible niacytin unless treated with alkali (nixtamalization, traditional in Mesoamerican cuisine). The flour fortification programs that began in 1938 ended pellagra in industrialized countries [2].

What this means for modern NAD supplement choices

A person eating a varied diet with adequate protein already takes in 12-18 mg niacin equivalents per day plus 1,000-1,500 mg tryptophan. The de novo pathway alone, even before any niacin intake, contributes substantially to NAD⁺ homeostasis. Niacin fortification of flour, breakfast cereals, and processed foods has made overt deficiency exceedingly rare. The premise that aging-related NAD⁺ decline can be reversed by adding NMN or NR is partly a tacit admission that adequate dietary precursors are not the limiting factor in tissue NAD⁺ homeostasis — something else (NAMPT expression, CD38 activity, sirtuin demand) controls the pool [3].

The IDO inflammation switch

Chronic inflammation activates IDO and shunts tryptophan away from the serotonin pathway toward kynurenine. This both increases NAD⁺ synthesis substrate and depletes tryptophan available for serotonin and melatonin synthesis. Some authors hypothesize that depression in chronic inflammatory disease and cancer cachexia involves this IDO-driven tryptophan steal. The kynurenine pathway intermediates (quinolinic acid, 3-hydroxykynurenine) are themselves neuroactive and have been implicated in the neuropsychiatric symptoms of inflammation [4].

Practical implications for supplement users

People interested in NAD⁺ status should consider that protein intake adequacy (and adequate B6, riboflavin, iron, and heme — all cofactors in the kynurenine pathway) is upstream of any NAD⁺-raising supplement. Vegetarians and people on calorie-restricted diets sometimes have marginal tryptophan intake. Niacin fortification has made pellagra rare but selected populations (severe alcoholism, carcinoid syndrome shunting tryptophan, isoniazid use which inhibits pyridoxal-5-phosphate, Hartnup disease) remain at risk for pellagra-like syndromes [5]. Recognizing these clinical contexts is more practically useful than the latest NMN dose.

The takeaway

The next NAD⁺ breakthrough may not be a new precursor at all but a better understanding of why aging cells fail to maintain the pool despite adequate inputs. Until then, dietary tryptophan, adequate B vitamins, and avoidance of clinical states that drain the pathway provide more reliable baseline NAD⁺ support than premium-priced precursor capsules.